fbpx

< Back to Thought Leadership

CMS Updates Language on Medicare Bad Debt Crossover Write Off

Since the release of Centers for Medicare & Medicaid (CMS) final ruling, there has been a lot of confusion regarding the correct way to write off a bad debt crossover account.

For years it has been acceptable to write off a Medicare bad debt crossover account to a contractual allowance. But then in 2018 an article was released in MLN stating that crossover accounts need to be written off to an expense starting 10/1/2019. The same “expense” terminology was used in the proposed CMS regulations earlier this year.

By using the word “expense”, many felt this was a direct contradiction to ASU Topic 606. Therefore, putting providers in a position to choose between compliance with CMS or Generally Accepted Accounting Principles (GAAP). After reviewing the comments submitted to CMS, the final ruling made a slight update in the wording to read:

“…for cost reporting periods beginning on or after October 1, 2020, Medicare bad debts must not be written off to a contractual allowance account but must be charged to an uncollectible receivables account that results in a reduction in revenue.”

This is now in line with ASU Topic 606 and points the bad debt crossover write off to be a reduction in revenue. It is no longer acceptable to write off crossover accounts to a contractual allowance account.

Questions to Ask Yourself and Your Team About Medicare Bad Debt Crossover

  • What transaction codes are being used for Medicare bad debt crossover accounts?
  • Do you know where your Medicare bad debt crossover write off is directed to on the financial statements?
  • Is the write off routed to net patient revenue or operating expense?
  • Do you have a separate General Ledger (GL) account set up for these Medicare bad debt crossover accounts?
  • Will you be able to provide a detailed listing of all patient accounts that are hitting the GL?

If you have any questions regarding the latest ruling or how it may affect your organization, please contact your local Blue & Co. advisor

Share this article

Beyond Compliance: The Strategic Value of Independent External 340B Audits

The 340B Drug Pricing Program is more than a pharmacy benefit; it is a lifeline for vulnerable communities and patients.  However, as federal scrutiny and manufacturer challenges intensify, maintaining program […]

Learn More
not-for-profit data management

From Data to Decisions: Strengthening Not-For-Profit Finance in an AI-Driven World

By Joell Grisel, CPA, Director at Blue & Co. Financial technology keeps evolving at a pace that is hard for many not-for-profits to keep up with. At Blue & Co., […]

Learn More
FY 2027 Medicare Wage Index Final PUFs: Key Deadlines and Hospital Correction Rules

FY 2027 Medicare Wage Index Final PUFs: Key Deadlines and Hospital Correction Rules

In early April 2026, a notice was sent from CMS to each MAC regarding the April 30th, 2026, release of the final FY 2027 wage index data PUFs. May 29th, […]

Learn More